- Home
- GLO vs ALEC Comparison
GLO vs ALEC Comparison
Compare GLO & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLO | ALEC |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 243.3M | 275.8M |
| IPO Year | 2006 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GLO | ALEC |
|---|---|---|
| Price | $5.62 | $2.11 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.83 |
| AVG Volume (30 Days) | 95.4K | ★ 1.2M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $21,045,000.00 |
| Revenue This Year | N/A | $2.03 |
| Revenue Next Year | N/A | $29.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.39 | $1.09 |
| 52 Week High | $6.18 | $3.40 |
Technical Indicators
Market Signals| Indicator | GLO | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 26.53 | 47.86 |
| Support Level | $5.50 | $1.93 |
| Resistance Level | $6.08 | $2.60 |
| Average True Range (ATR) | 0.06 | 0.21 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 6.06 | 18.42 |
Price Performance
Historical ComparisonAbout GLO Clough Global Opportunities Fund
Clough Global Opportunities Fund is a closed-end management investment company based in the United States. Its investment objective is to provide a high level of total return by investing in equity securities of companies of any market capitalization and equity-related securities, including equity swaps and call options, as well as fixed-income securities, including both corporate and sovereign debt, in both U.S. and non-U.S. markets.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.